CurvaFix, a medical device manufacturer headquartered in Bellevue, announced the close of a $39 million Series C equity round led by MVM Partners. CurvaFix is developing implantable solutions meant to improve fracture repair in curved bones.
The company will invest the fresh capital in expanding its treatment of high-energy and low-impact trauma pelvic fractures. CurvaFix will also put money toward launching its IM Implant product across the U.S. This device, designed to simplify surgery and provide stable fixation in smaller patients, has received 510(k) clearance from the U.S. Food & Drug Administration.
Alongside its latest capital raise, CurvaFix announced its company’s transition to a new CEO. Mark Foster, formerly president and CEO of Trice Medical, will take on the role chief executive officer at CurvaFix. The company’s current CEO, Steve Dimmer, will move into a strategic advisory position.
“I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point,” Foster said in a statement. “I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians and payers.”
